Introduction: Statins reduce the risk of cardiovascular morbidity and mortality in patients with
or at risk for cardiovascular disease and their use is expanding, especially in elderly. Statins …

Hypercholesterolemia is an important risk factor for cardiovascular disease. It is caused by a
disturbed balance between cholesterol secretion into the blood versus uptake. The …

Many studies have pinpointed the significant contribution of liver‐mediated drug metabolism
and transport to the complexity of drug‐induced liver injury (DILI). Phase I cytochrome P450 …

Statins are an effective treatment for the prevention of cardiovascular diseases and used
extensively worldwide. However, myotoxicity induced by statins is a common adverse event …

Introduction: Statin monotherapy is generally well tolerated, with a low frequency of adverse
events. The most important adverse effects associated with statins are myopathy and an …

Decreases in global cardiovascular disease (CVD) mortality and morbidity in recent
decades can be partly attributed to cholesterol reduction through statin use. n-3 long chain …

The US Food and Drug Administration approved 18 new drugs that incorporate the
cyclopropyl structural motif in the time frame from 2012 to 2018. This review provides an …

3‐hydroxy‐3‐methylglutaryl coenzyme A (HMG‐CoA) reductase inhibitors (statins) are
established first line treatments for hypercholesterolaemia. In addition to the direct effects of …

Statins are widely used and have been proven to be effective in the prevention of
atherosclerotic vascular disease events, primarily by reducing plasma low-density …

Statins have demonstrated substantial benefits in supporting cardiovascular health. Older
individuals are more likely to experience the well-known muscle-related side effects of …